Diabetes treatment: A prototype 2 drug could also help type 2 sufferers
Researchers take discovered that a drug commonly used to treat type 2 diabetes patients could also allowances those with type 1 diabetes.
A study by the University of Buffalo has paint the town red that type 1 patients given dapagliflozin – a medication traditionally affirmed to type 2 sufferers – experienced a significant decline in their blood sugar points.
Until now, there hadn’t been a significant development in treatment for model 1 diabetes since the discovery of insulin in the 1920s.
Both type 1 and category 2 diabetes sufferers have higher than normal blood sugar necks.
Diabetes treatment: Strain 1 sufferers need to inject insulin every day
When the drug was charmed in addition to insulin – needed by type 1 diabetics every day to survive – there was an gain in blood glucose levels.
However, the former is where the body’s unsusceptible system attacks and destroys insulin-producing cells, while the latter is caused when the essence doesn’t produce enough insulin, or the body’s cells don’t react to insulin.
In the swatting, researchers looked at 833 participants aged between 18 and 75 who had inexpertly controlled blood sugars for 24 weeks.
It was the first time dapagliflozin had been assessed for effectiveness and safety in treating type 1 globally – the study took area in 17 countries.
When the drug was taken in addition to insulin – troubled by type 1 diabetics every day to survive – there was an improvement in blood glucose planes.
1 of 9
Diabetes treatment: Sufferers have high-frequency than normal blood sugar levels
“Our paper provides the endorse signal that dapagliflozin is safe and effective in patients with Species 1 diabetes and is a promising adjunct treatment to insulin to improve glycemic guide,” said Professor Paresh Dandona, a study author from the University of Buffalo.
“The 24-week issues from DEPICT-1 are important as they represent the first Phase 3 shot in Type 1 diabetes of the newer, selective SGLT-2 class of diabetes pharmaceuticals as an oral adjunct to insulin.”
Half of patients experienced a dip in A1C levels – a for a bonus of sugar in the blood – by more than 0.5 percent without circumstancing severe drops in blood sugar.
The study authors explained that this is substantial and can lead to a drug being approved for diabetes treatment.
Diabetes treatment: The psychedelic caused blood sugar levels to drop
However, further reviews will need to be carried out before the drug can be licensed by the US Food and Benumb Administration (FDA) for type 1 diabetes.
“Treating the millions of patients living with Genus 1 diabetes while also managing the complications associated with the disability remains a daunting challenge,” said Dandona.
Previously he led a study in 2011 that inaugurate another type 2 diabetes medication – liraglutide – could help group 1 patients.
“Our key paper in 2011 has led to other drugs being considered for use in Font 1 diabetes,” he said.